{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:23:07Z","timestamp":1791321787676,"version":"4.3.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1136\/annrheumdis-2016-210708","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T21:00:13Z","timestamp":1489611613000},"page":"1093-1101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":294,"title":["Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-0229","authenticated-orcid":false,"given":"Alexandre","family":"Sepriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Chatzidionysiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie L","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Scholte-Voshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B M","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2016-210708_bib1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/annrheumdis-2016-209202","article-title":"Economic considerations and patients\u2019 preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists","volume":"76","author":"Hifinger","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib2","author":"Chatzidionysiou","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological DMARDs\u2014a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/ard.2008.091926","article-title":"European biologicals registers: methodology, selected results and perspectives","volume":"68","author":"Zink","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs\u20142016 update","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib7","series-title":"Evidence-based medicine: how to practice and teach EBM","author":"Sackett","year":"1997"},{"key":"10.1136\/annrheumdis-2016-210708_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1136\/annrheumdis-2016-210708_bib9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210708_bib10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1136\/annrheumdis-2016-210708_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1756-185X.12539","article-title":"Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan","volume":"17","author":"Chiu","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib12","first-page":"216","article-title":"Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study","volume":"33","author":"Lampropoulos","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2016-210708_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0121-8123(14)70144-6","article-title":"Infections in rheumatoid arthritis patients: biological therapy versus disease modifying anti-rheumatic drugs: one year follow-up","volume":"21","author":"Miranda","year":"2014","journal-title":"Revista Colombiana de Reumatologia"},{"key":"10.1136\/annrheumdis-2016-210708_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/ket333","article-title":"Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data","volume":"53","author":"Morgan","year":"2014","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2016-210708_bib15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00296-014-2945-y","article-title":"Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0","volume":"34","author":"Cobo-Ib\u00e1\u00f1ez","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1136\/annrheumdis-2016-210708_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cmpb.2014.06.008","article-title":"Infection risk in patients with rheumatoid arthritis treated with etanercept or adalimumab","volume":"116","author":"Chiang","year":"2014","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1136\/annrheumdis-2016-210708_bib17","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/acr.22281","article-title":"Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis","volume":"66","author":"Curtis","year":"2014","journal-title":"Arthritis Care and Research"},{"key":"10.1136\/annrheumdis-2016-210708_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semarthrit.2012.12.024","article-title":"Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis","volume":"43","author":"Johnston","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210708_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-015-0583-8","article-title":"Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry","volume":"17","author":"Sakai","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2016-210708_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2016-210708_bib21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.22628","article-title":"Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs","volume":"67","author":"Pappas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2016-210708_bib22","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.5588\/ijtld.13.0368","article-title":"Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan","volume":"17","author":"Ke","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib23","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/1471-2334-13-533","article-title":"\u201cSerious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study\u201d","volume":"13","author":"Wasson","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib25","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s10067-015-3026-7","article-title":"Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study","volume":"34","author":"Berghen","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2016-210708_bib26","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib27","doi-asserted-by":"crossref","first-page":"e0143286","DOI":"10.1371\/journal.pone.0143286","article-title":"Tumor necrosis factor inhibition and head and neck cancer recurrence and death in rheumatoid arthritis","volume":"10","author":"Phillips","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1136\/annrheumdis-2016-210708_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab","volume":"74","author":"Listing","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib30","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/annrheumdis-2012-202136","article-title":"Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist","volume":"72","author":"Solomon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/acr.22483","article-title":"Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study","volume":"67","author":"Desai","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2016-210708_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjmed.2014.11.025","article-title":"Risk of Venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"key":"10.1136\/annrheumdis-2016-210708_bib33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/pds.3409","article-title":"Association between anti-TNF-\u03b1 therapy and interstitial lung disease","volume":"22","author":"Herrinton","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1136\/annrheumdis-2016-210708_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2016-210708_bib35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxf)"},{"key":"10.1136\/annrheumdis-2016-210708_bib36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib37","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2016-210708_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/rheumatology\/kep325","article-title":"Initiation of rheumatoid arthritis treatments and the risk of serious infections","volume":"49","author":"Grijalva","year":"2010","journal-title":"Rheumatology (Oxf)"},{"key":"10.1136\/annrheumdis-2016-210708_bib39","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3899\/jrheum.101009","article-title":"Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Long-term Safety","volume":"38","author":"Komano","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2016-210708_bib40","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/acr.21666","article-title":"Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis","volume":"64","author":"Sakai","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2016-210708_bib41","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MD.0b013e318211106a","article-title":"TNF-\u03b1 antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis","volume":"90","author":"Lane","year":"2011","journal-title":"Medicine (Baltim)"},{"key":"10.1136\/annrheumdis-2016-210708_bib43","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/rheumatology\/ker146","article-title":"The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxf)"},{"key":"10.1136\/annrheumdis-2016-210708_bib44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib45","doi-asserted-by":"crossref","unstructured":"Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. 2009;301:737\u201344. doi:10.1001\/jama.2009.146","DOI":"10.1001\/jama.2009.146"},{"key":"10.1136\/annrheumdis-2016-210708_bib46","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2016-210708_bib47","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib48","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garc\u00eda-Doval","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib49","first-page":"679","article-title":"Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong\u2014the role of TNF blockers in an area of high tuberculosis burden","volume":"28","author":"Tam","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2016-210708_bib50","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210708_bib51","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210708_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210708_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor \u03b1 inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210708_bib54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","article-title":"Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry","volume":"9","author":"Pallavicini","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1136\/annrheumdis-2016-210708_bib55","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2016-210708_bib56","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"10.1136\/annrheumdis-2016-210708_bib57","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/ard.2009.125526","article-title":"EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1136\/annrheumdis-2016-210708_bib59","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/rheumatology\/keu446","article-title":"The EULAR study group for registers and observational drug studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers","volume":"54","author":"Kearsley-Fleet","year":"2015","journal-title":"Rheumatology (Oxf)"},{"key":"10.1136\/annrheumdis-2016-210708_bib60","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib61","article-title":"Long-term adverse events after daily concomitant treatment with 10 mg prednisone in the 2-year computer assisted management in early rheumatoid arthritis trial-II","volume":"67","author":"de Hair","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2016-210708_bib62","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2015-207838","article-title":"Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis","volume":"75","author":"Richter","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib64","first-page":"264","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib65","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib66","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","article-title":"Mycobacterial diseases and antitumour necrosis factor therapy in USA","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib68","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2016-210708_bib69","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib70","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210708_bib71","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology (Oxf)"},{"key":"10.1136\/annrheumdis-2016-210708_bib72","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register","volume":"71","author":"Mercer","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724027675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724027675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2016-210708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:02:38Z","timestamp":1779249758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724027675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0003496724027675"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-210708","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-210708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Inc. For permission to use (where not already granted under a licence) please go to http:\/\/www.bmj.com\/company\/products-services\/rights-and-licensing. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}